Lonhala Magnair (Glycopyrrolate) for COPD

Overview
Lonhala Magnair is a prescription drug approved by the Food and Drug Administration (FDA) as long-term maintenance treatment for airflow obstruction in people with chronic obstructive pulmonary disease (COPD). Lonhala Magnair may also be referred to by its drug name, Glycopyrrolate.

Lonhala Magnair is an anticholinergic. Lonhala Magnair is believed to work by relaxing and dilating the airways, making it easier to breathe.

How do I take it?
Lonhala Magnair is taken twice daily by oral inhalation.

Lonhala Magnair comes in the form of single-use vials inserted into a handset.

Side effects
The FDA-approved label for Lonhala Magnair lists common side effects including trouble breathing and urinary tract infections.

Rare but serious side effects listed for Lonhala Magnair can include paradoxical bronchospasm (bronchospasm caused by taking medication), worsening narrow-angle glaucoma, and urinary retention.

For more details about this treatment, visit:

LonhalaMagnair.com – Sunovion
https://www.lonhalamagnair.com/